Prelude Capital Management’s AC Immune ACIU Stock Holding History

Prelude Capital Management’s Portfolio ACIU Stock Details ACIU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-19,515	Closed	-$184K	–	1725
2018 Q4	$184K	Buy	+19,515	New	+$184K	0.01%	755

Other funds holding ACIU

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Prelude Capital Management's ACIU Position: Q1 2019 in Review

Prelude Capital Management sold out of AC Immune (ACIU) in Q1 2019, closing a stake of 19,515 shares — an estimated $184K sold.

Prelude Capital Management first reported a position in ACIU in Q4 2018 and held it in 1 quarter. The position peaked at $184K in Q4 2018. 41 funds tracked by Wall St. Rank hold ACIU as of Q1 2019.

Prelude Capital Management reported no remaining AC Immune position as of Q1 2019 after selling out during the quarter.
Prelude Capital Management sold 19,515 AC Immune shares in Q1 2019, an estimated $184K.
Prelude Capital Management first reported a position in AC Immune in Q4 2018 and held it in 1 quarter.
Prelude Capital Management's AC Immune position peaked at $184K in Q4 2018.
41 funds tracked by Wall St. Rank held AC Immune as of Q1 2019.

Based on Prelude Capital Management's 13F filing for Q1 2019, filed 15 May 2019.